Free Trial

CSL (CSLLY) Stock Forecast & Price Target

CSL logo
$34.41 0.00 (0.00%)
As of 11/13/2026 03:58 PM Eastern

CSL - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
4
Buy
1

Based on 5 Wall Street analysts who have issued ratings for CSL in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a buy rating for CSLLY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CSLLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CSL and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CSLLY Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldHoldHoldBuy

CSLLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSLLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CSL Stock vs. The Competition

TypeCSLHealthcare CompaniesBroader Market
Consensus Rating Score
2.20
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted UpsideN/A115.11% Upside14.67% Upside
News Sentiment Rating
Neutral News

See Recent CSLLY News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/15/2026 UpgradeHold ➝ Moderate Buy
8/7/2026
Zacks Research logo
Zacks Research
4 of 5 stars
 UpgradeStrong Sell ➝ Hold
5/29/2026 DowngradeStrong-Buy ➝ Hold
5/11/2026 DowngradeStrong-Buy ➝ Hold
5/11/2026 DowngradeStrong-Buy ➝ Hold
1/16/2025UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:22 AM ET.


Should I Buy CSL Stock? CSLLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 11, 2026. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com.

CSL
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CSL Limited:

  • CSL Limited recently agreed to a USD 1.6 billion deal with Alentis, a move that signals strong strategic growth and potential for expanding its product portfolio in the biopharmaceutical sector.
  • The company has demonstrated significant price momentum, hitting a 52-week high of $36.88 on November 5, 2026, and currently trading at $34.61, which reflects strong market confidence and recent upward trajectory.
  • CSL Limited offers a dividend yield of 2.06%, providing investors with a steady income stream that can help offset volatility in the biotechnology sector.
  • With a beta of 0.54, CSL Limited exhibits lower volatility compared to the broader market, making it a potentially stable investment for risk-averse investors seeking exposure to the healthcare industry.
  • The company reaffirmed its FY27 outlook despite a 3% decline in FY26 net profit after tax, indicating management's confidence in future performance and long-term growth prospects.

CSL
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CSL Limited for these reasons:

  • CSL Limited faces a class action in the Supreme Court of Victoria over alleged disclosure failures, which could lead to legal costs and reputational damage that may impact investor confidence.
  • The company's vaccines unit has been criticized for UK compliance failures, raising concerns about operational risks and potential regulatory scrutiny that could affect its business operations.
  • CSL Limited's FY26 net profit after tax declined by 3%, indicating potential challenges in maintaining profitability despite its strong market position and recent strategic deals.
  • The company's P/E ratio is listed as 0.00, which may indicate issues with earnings data or profitability concerns that could deter value-focused investors.
  • CSL Limited's short interest has fluctuated significantly, with a recent increase in shares shorted to 160,435, suggesting some market participants are betting against the stock's future performance.

CSLLY Forecast - Frequently Asked Questions

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CSLLY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CSLLY, but not buy additional shares or sell existing shares.

According to analysts, CSL's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, CSL's stock had 1 upgrade by analysts.

CSL has been rated by research analysts at Royal Bank Of Canada in the past 90 days.

Analysts like CSL less than other "healthcare" companies. The consensus rating score for CSL is 2.20 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how CSLLY compares to other companies.


MarketBeat monitors more than a dozen sources for CSL analyst ratings, with the most recent rating issued on 9/15/2026.
From Our Partners